ClinicaliQ Trial Snapshot
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Active Not Recruiting • Phase I / Phase II • Oncology • NCT04243499.
- New antibody drug (ICT01) tested alone and with pembrolizumab in advanced cancer patients to find safe doses and effectiveness.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 3 solid tumor indications for the combination of ICT01 plus pembrolizumab. Conditions: Solid Tumor, Adult, Hematopoietic/Lymphoid Cancer Interventions: IV ICT01 Lead Sponsor: ImCheck Therapeutics, an Ipsen company Planned Enrollment: 293 participants